- Home
- SNGX vs CYCN Comparison
SNGX vs CYCN Comparison
Compare SNGX & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNGX | CYCN |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.8M | 7.6M |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNGX | CYCN |
|---|---|---|
| Price | $1.47 | $1.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 454.0K | 43.6K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,855,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1371.65 |
| 52 Week Low | $1.09 | $1.28 |
| 52 Week High | $6.23 | $6.25 |
Technical Indicators
Market Signals| Indicator | SNGX | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 50.04 | 36.09 |
| Support Level | $1.31 | $1.43 |
| Resistance Level | $1.70 | $1.51 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 54.55 | 9.28 |
Price Performance
Historical ComparisonAbout SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.